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Purpose: The aim of this study was to measure the distribution of endogenous plasminogen 
activators during thrombolysis with an endothelial-conserving model of laminated 
thrombosis. 
Methods: Thrombi were raised in the inferior vena cava of rats with thrombin and flow 
reduction. The thrombi, adjacent vein wall, and distant veins (the superior vena cava) were 
removed at intervals from 1 hour to 21 days from formation and then cryohomogenized 
and assayed with specific bioimmunoassays for tissue-type (t-PA) and urokinase-type 
plasminogen activators (u-PA). 
Results: The measured t-PA activity of the vein wall around the thrombus was reduced 
compared with the control inferior vena eava at 4 days. Both the u-PA and t-PA content 
of the thrombus increased progressively during thrombolysis. The t-PA activity increased 
significantly in the distant vein wails in the animals with thrombi. Immunocytochemistry 
and in situ hybridization localized the t-PA to a mononuclear cell infiltrate and showed 
up-regulation of mRNA for rat t-PA in these monocytes. 
Conclusions: The local plasminogen activator esponse was predominantly within the 
thrombus itself. Increased t-PA activity was additionally found in distant veins but was 
reduced in the vessel wall adjacent to the thrombus. This is the first report o show that 
u-PA activity is increased within organizing thrombus in vivo and that most of the t-PA 
activity is localized to a monocyte infiltrate. (J VASC SURG 1995;22:573-9.) 
Plasmin-mediated fibrinolysis is now well under- 
stood, particularly with regard to in vitro plasmino- 
gen activation, inhibition, and control.1 The study of 
thrombolysis has been predominantly carried out at 
a molecular level for want of  a reproducible, patho- 
logically representative thrombosis model. There is 
minimal information available on the natural history 
ofplasminogen activation in response to thrombus in 
vivo. Although urokinase-type lasminogen activator 
(u-PA) is known to be produced by vascular endo- 
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thelium 2and is present in plasma, 3the conventional 
view has been that it is an important initiating 
enzyme in cell-mediated tissue remodeling 4-6 but has 
no established role in intravascular fibrinolysis. In 
contrast he high levels of tissue-type plasminogen 
activator (t-PA) demonstrated in vessel walls and 
synthesized by cultured vascular endothelium have 
suggested that this is the initiator of intravascular 
fibrinolysis. 7 There is evidence that t-PA and single- 
chain urokinase plasminogen activator have synergis- 
tic thrombolytic activity in vitro s'9 and in vivo on the 
basis of  therapeutic trials. ]°,11 Gurewich 12 has con- 
cluded from these findings that the natural history of  
thrombolysis n vivo may involve both plasminogen 
activators, ~2 although there is no direct evidence that 
this is the case. 
The organization of  thrombus is poorly under- 
stood, and the importance of  the cellular component 
in fibrinolysis is unclear. In established thrombosis 
there is an early polymorphonuclear neutrophil 
infiltrate, 13,14 and these cells have a putative role for 
plasmin-independent fibrinolysis via enzymes uch as 
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cathepsin G and elastase, is A monocyte infiltrate 
appears later 16,17 because ndothelial sinusoids form 
within the organizing thrombus. 18 Whereas mono- 
cytes can internalize fibrinogen 19 and clearly play an 
important part in receptor-bound u-PA-mediated 
tissue remodeling, 2°their precise role in thrombolysis 
is at present speculative. The histologic similarities 
between organizing thrombus and granulation tissue 
led us to investigate he role ofurokinase inthrombus 
dissolution. The aim of this study was to evaluate the 
type and amount ofplasminogen activators that were 
present in experimentally induced thrombi and the 
surrounding vessel wall. The development ofa model 
of laminated venous thrombosis in the rat, in which 
the endothelium and underlying vein wall remains 
undamaged, 21 has allowed us to study the distribu- 
tion of fibrinolytic activity during thrombolysis. 
METHODS 
Thrombus was induced in the surgically mobi- 
lized infrarenal vena cava of anaesthetized 300 gm 
male Carnforth Sprague Europe rats. Thrombus 
formation was stimulated by a combination of flow 
reduction, achieved by inserting a stenosis distal to 
the renal veins, and the temporary introduction of 50 
txl of human thrombin in Ringers solution (150 
U/ml) into the isolated venous segment before the 
restoration of flow. 2~ Matching control rats under- 
went the same surgery with stenosis insertion, but the 
vena cava was perfused with Ringer's solution 
without thrombin. Groups of 10 rats with thrombi 
and 10 matching controls were killed at intervals 
from surgery of 1 hour, and 1, 2, 4, 7, 14, and 21 
days. Ten unoperated rats provided normal vessels. 
The thrombus, surrounding infrarenal vena cava, 
intrathoracic vena cava, superior vena cava, and 
femoral vein were removed and washed free of blood 
with Ringer's olution. The thrombus was separated 
from the vena cava under a dissecting microscope, 
and all tissues were snap-frozen in liquid nitrogen. 
Specimens were stored at - 70 ° C for short periods 
before homogenization. 
Samples of the larger tissue specimens of ap- 
proximately 50 gm, or the entire specimen if 
smaller, were cryohomogenized in liquid nitrogen 
(Braun Mikrodiskmembrator; B aun AG, Kronberg, 
Germany) and resuspended in an acetate/arginine 
buffer. 22 After centrifugation (25,000 g for 5 min- 
utes at 4 ° C), the cytosol supematant was snap- 
frozen and stored at -70  ° C before assaying. The 
t-PA and urokinase concentrations were measured 
with a bioimmunoassay, by use of affinity purified 
polyclonal bovine anti-human recombinant -PA 
(Welcome Biotechnology, Beckenham, United 
Kingdom) and rabbit anti-human u-PA (National 
Institute for Biological Standards & Controls, South 
Mimms, United Kingdom) antibodies, respectively, 
for the immunocapture phase. 23 The detection 
buffer was composed of LYS-plasminogen and 
the chromogenie substrate S-225 1 (Chromogenics, 
M61ndal, Sweden) in tris-buffered saline solution. 
Standard dilution curves with the International 
Standards for t-PA (87 of 670) and u-PA (87 of 
594) were used. The standards were supplied by the 
National Institute of Biological Standards and 
Controls. 
Thrombi were produced in the inferior vena cava 
(IVC) of a further group of rats with matching 
control animals. These pairs were killed at intervals of 
1 hour and 2, 4, 7, 14, and 28 days. The IVC was 
removed, the thrombus was left intact and snap- 
frozen, and cryostat sections were cut. Immunocy- 
tochemistry was performed with the MA-I6D2 
anti-human t-PA antibody and rat ED1 monocyte 
marker, and in situ hybridization with a riboprobe 
was raised against a rat t-PA eDNA 427 base 
template. 
This project was licensed by the United Kingdom 
Government Home Office Inspectorate. The plasmi- 
nogen activator concentrations were expressed as 
units of activity per gram original wet tissue weight. 
All values expressed are the mean of 10 values with 
95% confidence intervals. Significance was assessed 
by Student's t testing, with a probability level of 0.05 
or less considered significant. 
RESULTS 
All the rats receiving the thrombin caval perfusion 
and a stenosis produced thrombi as measured by a 
significant increase in proximal femoral vein pressure. 
No control rat had development ofany pressure rise 
above that induced by the stenosis to reduce flow, and 
no visible thrombus was found at sacrifice. The two 
Ringer's solution-per fused control animals with a 
stenosis and two other control animals perfused with 
thrombin but without a stenosis, none of which 
thrombosed, showed no evidence of endothelial 
damage when examined 1 hour after surgery with 
scanning and transmission electron microscopy. The 
thrombi continued to increase in weight, indicating 
continued propagation (Fig. 1), doubling in size 
from ameanof46 _+ 27gm at 1 hour to 99 -+ 43 gm 
at 48 hours, before undergoing rapid resolution. 
Thrombus could no longer be obtained by 21 days 
because it had been reduced to a longitudinal, 
endothelialized, subintimal streak. Initially the plas- 
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Fig. 1. Mean thrombus weight (gm -+ 95% confidence 
interval). 
minogen activator content of the thrombus was low. 
At 1 hour the mean t-PA activity was 2.56 _+ 0.61 
U/gin, and the mean u-PA activity was 5.68 + 4.42 
U/gin (Fig. 2). From 4 to 14 days both the u-PA and 
t-PA activity increased considerably reaching 14 + 
12 U/gm (t-PA) and 34.2 + 9.8 U/gm (u-PA) at 14 
days. The u-PA activity of thrombus was always 
greater than t-PA activity. The t-PA content of the 
IVC vein wall from around the thrombus howed a 
significant reduction on the first and second days 
compared with the control animals (Fig. 3). There 
was also a marked increase in t-PA level in both the 
control and thrombosed caval walls at 7 and 14 days, 
when surrounding ranulation tissue was at a maxi- 
mum. There was an early rise in u-PA levels in 
both control and thrombosed IVC walls peaking at 
1 U/gm (u-PA) at 2 days (Fig. 4). 
The superior vena cava was also assayed for 
plasminogen activator activity (Fig. 5), and these 
veins at some distance from the thrombus also 
showed asignificantly greater mean t-PA activity at 7 
days in the animals with thrombi than the control 
animals. The mean t-PA content of the femoral veins 
in the animals with thrombi was also increased (Fig. 
6), although the t-PA activity gradually decreased 
over time in both groups of animals. 
A similar response was seen in the intrathoracic 
IVC (2 cm from the infrarenal thrombus), which was 
also harvested and assayed for its t-PA content. The 
mean t-PA content of these veins sampled from 
animals with thrombi was significantly greater than 
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Fig. 2. Thrombus plasminogen activator content (mean 
activity units _+ 95% confidence interval). 
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Fig. 3. Inferior vena cava tissue plasminogen activator 
content (mean activity units _+ 95% confidence interval). 
the levels in the control animals (data not shown). 
The u-PA content of the superior vena cava and 
femoral veins did not differ significantly (data not 
shown). 
Strong t-PA staining was observed with immuno- 
cytochemistry in the monocyte infiltrate of the 
thrombus at 14 and 28 days. The cytoplasm of these 
monocytes also demonstrated strong RNA labeling 
for t-PA. In a 14-day-old thrombus labeled for rat 
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Fig. 4. Inferior vena cava urokinase content (mean activ- 
ity units - 95% confidence interval). 
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Fig. 5. Superior vena cava tissue plasminogen activator 
content (mean activity units _+ 95% confidence interval). 
t-PA RNA by in situ hybridization, stronger staining 
can be seen within the cytoplasm of the monocyte 
infiltrate than the recanalizing new endothelium (Fig. 
7). Little t-PA activity was observed in the luminal 
endothelium with either technique; the only other 
site of weak t-PA labeling was in the vascular smooth 
muscle. 
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Fig. 6. Femoral vein tissue plasminogen activator content 
(mean activity units + 95% confidence interval). 
DISCUSSION 
The measurement of fibrinolytic activity in tissues 
of animal species is fraught with difficulty. The 
promoter assay is not species pecific, but as the title 
of the original study by Verheijen et al.24 stated, it was 
designed for the assay of plasma components. Vas- 
cular tissue cytosols contain a mixture of enzymes 
(some of which are capable of plasmin-independent 
hydrolysis of the substrate), and because they have 
a frequently high inherent optical density, this assay 
is unsuitable for use with tissue specimens. The 
enzyme-linked immunosorbent assay is in common 
use for plasminogen activator measurement. Al- 
though it is ideal for use with human tissue cytosols, 
it is quite unsuitable for use with animal material. 
An enzyme-linked immunosorbent assay with anti- 
human t-PA monoclonal antibodies that have af- 
finity for rat t-PA (including MA-16D2) is being 
evaluated but has not been fully validated (H. R. 
Lijnen, in conversation, August 1994). The bioim- 
munoassay avoids the disadvantages of incubating 
the cytosol (containing plasmin independent en- 
zymes) with the substrate. The fact that both 
bioimmunoassays for t-PA and u-PA use polyclonal 
rather than monoclonal antibodies at the capture 
stage of the assay has allowed the rat activators to be 
measured because they obviously share some com- 
mon epitopes with the human activators. This could 
be anticipated because there are many common 
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Fig. 7. Thrombus at 14 days in rat vena cava labeled with rat t-PA riboprobe (in SltU 
hybridization) shows strong monocyte and moderate endothelial staining. 
domains within the components of the fibrinolytic 
system, which appears to have evolved at an early 
phylogenetic stage2~; rat and human t-PA also 
demonstrate more than 80% DNA sequence struc- 
ture. 26 The sensitivity of the bioimmunoassay is 
evidently reduced with rat plasminogen activators, 
because the binding during the immunocapture 
phase will be of lower affinity, and rat plasminogen 
activators lyse human plasminogen with approxi- 
mately 50% of the efficacy of human activators (J. ~. 
Emeiss, written communication, February 1990). 
The plasminogen activator activity is therefore x- 
pressed in comparative units of activity. 
Most of the plasminogen activator found in the 
vicinity of the resolving thrombus in our model was 
in the maturing older thrombus itself, whereas the 
fibrinolytic response of the surrounding vein wall was 
reduced. There has been a long-standing belief that 
t-PA synthesis in vascular endothelium would up- 
regulate in response to thrombosis. 7,12 Examination 
of the intact vein wall/thrombus specimens shows a 
loss of luminal endothelium from 2 days onward 
under occlusive thrombus. Hypoxic damage seen as 
vacuolation is apparent with transmission electron 
microscopy as early as I hour after thrombus forma- 
tion. This loss of endothefium is compatible with the 
reduction of vein wall t-PA content beneath the 
thrombus. As organization proceeds the increasing 
level oft-PA in the thrombus i probably explained by 
the increasing monocyte content. Despite the obser- 
vations that monocytes have been shown to produce 
t-PA 27 and have a Mac-l-mediated ability to ingest 
fibrinogen directly, 19 they have not previously been 
assumed to have a major fibrinolytic role in throm- 
bolysis. Monocytes in many circumstances 
may be prothrombotic via the production of tis- 
sue factor, 28 plasminogen activator inhibitor, 29,3° and 
thrombin activation? 1 
We have shown with immunocytochemistry that 
most of the t-PA is present within the monocytes, and 
in situ hybridization has demonstrated up-regulation 
of monocyte mRNA for t-PA. Unfortunately in the 
absence of specific antibodies or RNA probes for rat 
u-PA, it cannot currently be demonstrated with the 
same techniques in rat thrombi. In view of the 
well-proven role of monocytes in secreting 29 and 
binding u-PA, a2 it is quite possible that the mono- 
cytes are also the source of the u-PA demonstrated 
within the thrombus. Previously thrombi have been 
shown to contain plasminogen, 33,34 which is presum- 
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ably largely incorporated in fibrin via the plasmino- 
gen binding site of  fibrin. 3s A recent study correlated 
the t-PA and plasminogen content of human thrombi 
obtained at operation and postmortem examination 
with their ex vivo lysability. 36 The absolute level of  
t-PA in venous thrombi was half the average content 
of  arterial thrombi, and both exhibited a tenfold 
range. By definition these human specimens were of  
indeterminate age, and our model demonstrates that 
the degree of organization is a considerable factor in 
the amount ofthrombus fibrinolytic activity. There is 
a consensus that t-PA is incorporated into forming 
fibrin more effectively than into preformed fibrin? 7 
Besides the differences in activator content be- 
tween the vessels of animals with and without 
thrombi, there are major differences between the 
normal activator levels in veins from different ana- 
tomic areas. There are also changes in the level of 
plasminogen activator over time. The initially high 
level of t-PA in the normal superior vena cava is 
representative of the strong central distribution of 
t-PA in the normal rat, it being highest in the central 
vessels and lowest at the periphery? 8 A continuous 
fall in t-PA content of the femoral vein may be 
explained by the increased pressure in this vein caused 
by both the presence of the thrombus and the stenosis 
designed to reduce the flow. Venous hypertension 
not only causes acute release of t-PA 39 but also 
reduces the fibrinolytic activity in vein walls over the 
longer term. 4°~41 The marked increase in plasminogen 
activator in the IVC wall of both control animals and 
those with thrombi may be related to the presence of  
inflammatory tissue and granulation tissue in re- 
sponse to previous urgical mobilization. The u-PA 
level peaked at 2 days and the t-PA at 7 days. A partial 
explanation may involve the fact that u-PA levels in 
tissue increase in acute inflammatory processes, 
whereas t-PA levels are reduced. 42 
Although any conclusions that can be drawn 
from this work must take into account he differ- 
ences between the rat and human fibrinolytic sys- 
tems, the pattern of plasminogen activator response 
was not as anticipated. The high level of u-PA in 
the late phase of  organization and the poor response 
from the adjacent vessel wall do not follow the 
estabfished view of in vivo fibrinolysis. These find- 
ings, taken together with the localization of t-PA 
in the monocyte, should lead to a reappraisal of  the 
role of u-PA and of the monocyte in pathologic 
thrombolysis. The parallel increase in both t-PA and 
u-PA within the thrombus adds support to the 
suggestion by Gurewich 8'12 and Collen et al. 1° that 
the two enzymes may demonstrate synergistic ac- 
tivity. Further research into monocyte recruitment 
to organizing thrombosis and the mechanisms by 
which they are stimulated to become fibrinolytically 
active, as well as the use of combined or sequential 
plasminogen activator regimens, 4a may improve the 
sometimes disappointing results of single-agent 
therapeutic fibrinolysis. 
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